Aprogen Pharmaceuticals Inc (003060) — Cash Flow-to-Debt Ratio
Aprogen Pharmaceuticals Inc (003060) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of ₩-7.66 Billion could theoretically repay 0% of its total liabilities (₩288.27 Billion) in one year. See Aprogen Pharmaceuticals Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aprogen Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2010–2024)
Historical debt coverage capacity for Aprogen Pharmaceuticals Inc across 13 annual periods. For the full cash flow conversion analysis, see Aprogen Pharmaceuticals Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Aprogen Pharmaceuticals Inc (2010–2024)
Year-by-year debt coverage analysis for Aprogen Pharmaceuticals Inc. Check 003060 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | ₩-31.00 Billion | ₩212.29 Billion | ▲ +4.2% |
| 2023 | -0.15x | ₩-33.65 Billion | ₩220.71 Billion | ▼ -203.0% |
| 2022 | 0.15x | ₩25.73 Billion | ₩173.73 Billion | ▲ +141.5% |
| 2021 | -0.36x | ₩-6.23 Billion | ₩17.44 Billion | ▼ -174.8% |
| 2020 | 0.48x | ₩8.09 Billion | ₩16.95 Billion | ▲ +1079.5% |
| 2019 | 0.04x | ₩713.73 Million | ₩17.65 Billion | ▲ +102.2% |
| 2018 | 0.02x | ₩1.33 Billion | ₩66.55 Billion | ▲ +118.0% |
| 2017 | -0.11x | ₩-8.93 Billion | ₩80.41 Billion | ▼ -1347.7% |
| 2016 | 0.01x | ₩449.98 Million | ₩50.57 Billion | ▼ -91.6% |
| 2015 | 0.11x | ₩1.85 Billion | ₩17.48 Billion | ▲ +134.7% |
| 2014 | -0.30x | ₩-6.92 Billion | ₩22.71 Billion | ▼ -288.5% |
| 2013 | -0.08x | ₩-1.70 Billion | ₩21.71 Billion | ▼ -1234.7% |
| 2010 | 0.01x | ₩247.92 Million | ₩35.89 Billion | — |